Market Cap 12.21B
Revenue (ttm) 3.81B
Net Income (ttm) 663.00M
EPS (ttm) N/A
PE Ratio 22.53
Forward PE 20.19
Profit Margin 17.40%
Debt to Equity Ratio 0.14
Volume 988,300
Avg Vol 925,190
Day's Range N/A - N/A
Shares Out 834.93M
Stochastic %K 64%
Beta 0.40
Analysts Hold
Price Target $16.20

Company Profile

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equival...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900
Address:
8-2-337, Road No. 3, Banjara Hills, Hyderabad, India
_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:36 PM
Keep a close watch on CMCT! $RDY $COF $USB $VZLA AA
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 8:22 PM
$RDY Really good write-up that perfectly summarizes RDY's present situation. So if you want to bring your RDY knowledge up to date or just discover RDY, this is required reading. https://beyondspx.com/quote/RDY/analysis/dr-reddy-s-innovation-and-diversification-powering-future-growth-amidst-generic-headwinds-rdy
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 2:21 PM
$ESPR surged 13.8% on settlement news with $RDY! 🚀 Esperion clinched a deal preventing RDY’s generic launches of Nexletol/Nexlizet until 2040, except under certain conditions, resolving patent disputes and boosting investor confidence. 📈 With a 50% YTD rise, ESPR is outpacing the industry’s 14.1% growth. Find out what this means for future growth 👉 https://www.zacks.com/stock/news/2762841/espr-settles-nexletolnexlizet-patent-litigation-with-rdy-stock-up?cid=sm-stocktwits-2-2762841-body-14760&ADID=SYND_STOCKTWITS_TWEET_2_2762841_BODY_14760
1 · Reply
WallStWireAds
WallStWireAds Aug. 30 at 12:22 PM
$DRREDDY.NSE $RDY https://capnotes.beehiiv.com/p/dr-reddy-s-multi-lever-strategy-to-power-its-next-phase-of-growth
0 · Reply
G101SPM
G101SPM Aug. 7 at 10:45 AM
#NOISE According to SPM tag, India Prime Minister Narendra Modi says he will not compromise on tariffs. In-play: $RDY, $INFY, $WIT, $INDA
0 · Reply
WallStWireAds
WallStWireAds Aug. 2 at 3:45 PM
$RDY https://alphacatalyst.beehiiv.com/p/dr-reddy-s-reports-record-revenues-in-q1-signals-steady-execution-through-transition-year
0 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:43 PM
$TEVA Thought you might like to see. $INCY $GMAB $RDY $NBIX
0 · Reply
Flrz
Flrz Jul. 26 at 8:21 AM
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 4:23 PM
$RDY Q1 earnings beat — but is the stock a buy? EPS of 20 cents per ADS topped the Zacks Consensus Estimate of 18 cents. Revenues grew 11% year over year to $997 million, driven by growth in global generics revenues, surpassing estimates. Yet, shares have slipped 7.5% year to date. Understand the risks before investing in RDY 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-body-3688&ADID=SYND_STOCKTWITS_TWEET_2_2613023_BODY_3688
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 2:34 PM
$RDY beats Q1 estimates — generics driving the surge Earnings and revenue both came in above expectations, powered by strong growth in global generic sales. See what could drive RDY’s next move 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-teaser-3564&ADID=SYND_STOCKTWITS_TWEET_2_2613023_TEASER_3564
0 · Reply
Latest News on RDY
Dr. Reddy's Q1FY26 Financial Results

Jul 23, 2025, 1:46 PM EDT - 3 months ago

Dr. Reddy's Q1FY26 Financial Results


Dr. Reddy's Continues To Be A Good Buy At Current Valuation

May 15, 2025, 11:47 AM EDT - 5 months ago

Dr. Reddy's Continues To Be A Good Buy At Current Valuation


Dr. Reddy's Q4 & Full Year FY25 Financial Results

May 9, 2025, 2:53 PM EDT - 6 months ago

Dr. Reddy's Q4 & Full Year FY25 Financial Results


Dr. Reddy's Q3 & 9MFY25 Financial Results

Jan 23, 2025, 12:35 PM EST - 9 months ago

Dr. Reddy's Q3 & 9MFY25 Financial Results


Dr. Reddy's Q2 & H1FY25 Financial Results

Nov 5, 2024, 9:59 AM EST - 1 year ago

Dr. Reddy's Q2 & H1FY25 Financial Results


Dr. Reddy's Q1FY25 Financial Results

Jul 27, 2024, 9:51 AM EDT - 1 year ago

Dr. Reddy's Q1FY25 Financial Results


Dr. Reddy's Q4 & Full Year FY24 Financial Results

May 7, 2024, 10:31 AM EDT - 1 year ago

Dr. Reddy's Q4 & Full Year FY24 Financial Results


Dr. Reddy's Q3 & 9M FY24 Financial Results

Jan 31, 2024, 9:44 AM EST - 1 year ago

Dr. Reddy's Q3 & 9M FY24 Financial Results


India's Dr. Reddy's R&D centre being inspected by US FDA

Dec 5, 2023, 4:41 AM EST - 2 years ago

India's Dr. Reddy's R&D centre being inspected by US FDA


_CircuitBreaker
_CircuitBreaker Oct. 9 at 11:36 PM
Keep a close watch on CMCT! $RDY $COF $USB $VZLA AA
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 6 at 8:22 PM
$RDY Really good write-up that perfectly summarizes RDY's present situation. So if you want to bring your RDY knowledge up to date or just discover RDY, this is required reading. https://beyondspx.com/quote/RDY/analysis/dr-reddy-s-innovation-and-diversification-powering-future-growth-amidst-generic-headwinds-rdy
0 · Reply
ZacksResearch
ZacksResearch Oct. 6 at 2:21 PM
$ESPR surged 13.8% on settlement news with $RDY! 🚀 Esperion clinched a deal preventing RDY’s generic launches of Nexletol/Nexlizet until 2040, except under certain conditions, resolving patent disputes and boosting investor confidence. 📈 With a 50% YTD rise, ESPR is outpacing the industry’s 14.1% growth. Find out what this means for future growth 👉 https://www.zacks.com/stock/news/2762841/espr-settles-nexletolnexlizet-patent-litigation-with-rdy-stock-up?cid=sm-stocktwits-2-2762841-body-14760&ADID=SYND_STOCKTWITS_TWEET_2_2762841_BODY_14760
1 · Reply
WallStWireAds
WallStWireAds Aug. 30 at 12:22 PM
$DRREDDY.NSE $RDY https://capnotes.beehiiv.com/p/dr-reddy-s-multi-lever-strategy-to-power-its-next-phase-of-growth
0 · Reply
G101SPM
G101SPM Aug. 7 at 10:45 AM
#NOISE According to SPM tag, India Prime Minister Narendra Modi says he will not compromise on tariffs. In-play: $RDY, $INFY, $WIT, $INDA
0 · Reply
WallStWireAds
WallStWireAds Aug. 2 at 3:45 PM
$RDY https://alphacatalyst.beehiiv.com/p/dr-reddy-s-reports-record-revenues-in-q1-signals-steady-execution-through-transition-year
0 · Reply
SparkyReturns
SparkyReturns Jul. 31 at 2:43 PM
$TEVA Thought you might like to see. $INCY $GMAB $RDY $NBIX
0 · Reply
Flrz
Flrz Jul. 26 at 8:21 AM
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 4:23 PM
$RDY Q1 earnings beat — but is the stock a buy? EPS of 20 cents per ADS topped the Zacks Consensus Estimate of 18 cents. Revenues grew 11% year over year to $997 million, driven by growth in global generics revenues, surpassing estimates. Yet, shares have slipped 7.5% year to date. Understand the risks before investing in RDY 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-body-3688&ADID=SYND_STOCKTWITS_TWEET_2_2613023_BODY_3688
0 · Reply
ZacksResearch
ZacksResearch Jul. 24 at 2:34 PM
$RDY beats Q1 estimates — generics driving the surge Earnings and revenue both came in above expectations, powered by strong growth in global generic sales. See what could drive RDY’s next move 👉 https://www.zacks.com/stock/news/2613023/dr-reddys-q1-earnings-beat-estimates-generics-sales-boost-revenues?cid=sm-stocktwits-2-2613023-teaser-3564&ADID=SYND_STOCKTWITS_TWEET_2_2613023_TEASER_3564
0 · Reply
XkaliburTrading
XkaliburTrading Jul. 23 at 6:46 PM
$RDY https://benzinga.com/node/46581767
0 · Reply
WallStWireAds
WallStWireAds Jul. 18 at 3:45 PM
$RDY $DRREDDY.NSE https://thefinanceherald.com/expanding-the-preventive-care-frontier-dr-reddys-launches-sanofis-beyfortus-in-india/
0 · Reply
DougAfter60
DougAfter60 Jul. 18 at 1:40 PM
let’s see if $RDY is due for a run
0 · Reply
infront
infront Jun. 17 at 10:16 PM
$RDY https://finance.yahoo.com/news/teva-partners-fosun-develop-tev-160200038.html
0 · Reply
Flrz
Flrz Jun. 12 at 8:17 PM
$RDY I am ready :)
0 · Reply
Nomorelies
Nomorelies Jun. 10 at 2:56 PM
$RDY That’s quite an upgrade!!
0 · Reply
infront
infront Jun. 6 at 12:12 PM
$RDY https://www.streetinsider.com/dr/news.php?id=24905974&gfv=1
0 · Reply
ZacksResearch
ZacksResearch Jun. 5 at 4:46 PM
$RDY just landed a key biosimilar deal — here's why it matters 👇 Partnering with Alvotech to co-develop and commercialize a biosimilar version of $MRK’s blockbuster Keytruda, expanding its reach in the high-growth biosimilars market. See what this could mean for RDY’s pipeline and growth outlook 👉 https://www.zacks.com/stock/news/2485940/rdy-alvo-ink-collaboration-deal-for-mercks-keytruda-biosimilar?cid=sm-stocktwits-2-2485940-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2485940_TEASER
0 · Reply
Nomorelies
Nomorelies Jun. 5 at 3:28 PM
$RDY New position! Let’s go!!
0 · Reply
ZacksResearch
ZacksResearch Jun. 5 at 3:01 PM
$RDY teams up with $ALVO to tackle $MRK's Keytruda! 💊 The new collaboration aims to co-develop a biosimilar to Keytruda, Merck's cancer treatment powerhouse, which saw a 6% sales growth YoY, enhancing RDY's biosimilar portfolio in emerging markets and ALVO's global pipeline expansion. 📈 See the full potential of this deal here 👉 https://www.zacks.com/commentary/2485940/rdy-alvo-ink-collaboration-deal-for-mercks-keytruda-biosimilar?cid=sm-stocktwits-2-2485940-body&ADID=SYND_STOCKTWITS_TWEET_2_2485940_BODY
0 · Reply
kistofa
kistofa Jun. 5 at 2:00 PM
$RDY good price action today
0 · Reply
Wallst45
Wallst45 Jun. 5 at 11:38 AM
Alvotech $ALVO and Dr. Reddy's $RDY team up to co-develop a biosimilar to Keytruda, aiming to enhance global cancer treatment options. The collaboration will leverage both companies' biosimilar expertise Bad news for $MRK
0 · Reply